Remus Pharmaceutical Stock Price Analysis and Quick Research Report. Is Remus Pharmaceutical an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Remus Pharmaceutical. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Remus Pharmaceutical has a PE ratio of 40.1189059233862 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Remus Pharmaceutical has ROA of 8.5815% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Remus Pharmaceutical has a Current ratio of 4.8655.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Remus Pharmaceutical has a ROE of 10.0563%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Remus Pharmaceutical has a Debt to Equity ratio of 0.0088 which means that the company has low proportion of debt in its capital.

• Sales growth: Remus Pharmaceutical has reported revenue growth of 23.8036% which is fair in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Remus Pharmaceutical for the current financial year is 32.8196058615462%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Remus Pharmaceutical is Rs 1.5 and the yield is 0.1107%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Remus Pharmaceutical is Rs 16.8873. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Remus Pharmaceutical in Ticker for free. Also, one can get the intrinsic value of Remus Pharmaceutical by using Valuation Calculators, which are available with a Finology ONE subscription. 

Remus Pharmaceutical FAQs

Q1. What is Remus Pharmaceutical share price today?
Ans: The current share price of Remus Pharmaceutical is Rs 677.5.

Q2. What is the market capitalisation of Remus Pharmaceutical?
Ans: Remus Pharmaceutical has a market capitalisation of Rs 798.366 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Remus Pharmaceutical?
Ans: The PE ratio of Remus Pharmaceutical is 40.1189059233862 and the P/B ratio of Remus Pharmaceutical is 3.21773854960019, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Remus Pharmaceutical share?
Ans: The 52-week high share price of Remus Pharmaceutical is Rs 1145, and the 52-week low share price of Remus Pharmaceutical is Rs 611.05.

Q5. Does Remus Pharmaceutical pay dividends?
Ans: Currently, Remus Pharmaceutical pays dividends. Dividend yield of Remus Pharmaceutical is around 0.1107%.

Q6. What are the face value and book value of Remus Pharmaceutical shares?
Ans: The face value of Remus Pharmaceutical shares is Rs 10, while the book value per share of Remus Pharmaceutical is around Rs 210.5516. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Remus Pharmaceutical?
Ans: Remus Pharmaceutical has a total debt of Rs 2.14 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Remus Pharmaceutical?
Ans: The ROE of Remus Pharmaceutical is 10.0563% and ROCE of Remus Pharmaceutical is 13.532%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Remus Pharmaceutical a good buy for the long term?
Ans: The Remus Pharmaceutical long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Remus Pharmaceutical undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Remus Pharmaceutical appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Remus Pharmaceutical’s financials?
Ans: You can review Remus Pharmaceutical’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.